ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
March 25, 2019 (Issue: 1568)
A lidocaine 1.8% patch (ZTlido – Scilex) has been
approved by the FDA for treatment of pain associated
with postherpetic neuralgia (PHN). A lidocaine 5%
patch (Lidoderm, and generics) was approved earlier
for the same indication and has been...more
- RW Johnson and AS Rice. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014; 371:1526.
- JS Massengill and JL Kittredge. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res 2014; 7:125.
- T Mallick-Searle et al. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc 2016; 9:447.
- Once-daily gabapentin (Gralise) for postherpetic neuralgia. Med Lett Drugs Ther 2011; 53:94.
- Capsaicin patch (Qutenza) for postherpetic neuralgia. Med Lett Drugs Ther 2011; 53:42.
- K Patel et al. A randomized, comparative pharmacokinetic (PK) study of ZTlido lidocaine topical system 1.8% (36 mg) versus Lidoderm lidocaine patch 5% (700 mg). Abstract 63. Presented at PainWeek Sept 4-8, 2018; Las Vegas, NV. Available at: https://doi.org. Accessed March 13, 2019.
- J Gudin et al. Adhesion performance of 3 lidocaine patch formulations. Abstract 46. Presented at PainWeek, Sept 4-8, 2018; Las Vegas, NV. Available at: https://doi.org. Accessed March 13, 2019.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
